<DOC>
	<DOCNO>NCT02178436</DOCNO>
	<brief_summary>This partially randomized phase Ib/II trial study side effect best dose selinexor give together gemcitabine hydrochloride paclitaxel albumin-stabilized nanoparticle formulation see well work treat patient pancreatic cancer spread part body . Drugs use chemotherapy , selinexor , gemcitabine hydrochloride paclitaxel albumin-stabilized nanoparticle formulation , work different way stop growth tumor cell , either kill cell , stop dividing , stop spreading .</brief_summary>
	<brief_title>Selinexor , Gemcitabine Hydrochloride , Paclitaxel Albumin-Stabilized Nanoparticle Formulation Treating Patients With Metastatic Pancreatic Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine recommended phase 2 dose ( RP2D ) gemcitabine ( gemcitabine hydrochloride ) , nab-paclitaxel ( paclitaxel albumin-stabilized nanoparticle formulation ) KPT-330 ( selinexor ) untreated metastatic pancreatic cancer . II . To determine safety profile gemcitabine , nab-paclitaxel KPT-330 . III . To test whether gemcitabine , nab-paclitaxel KPT-330 improve overall survival compare historical control comprise patient metastatic pancreatic cancer . SECONDARY OBJECTIVES : I . To determine objective response rate combination gemcitabine , nab-paclitaxel KPT-330 use Response Evaluation Criteria In Solid Tumors ( RECIST ) criterion . II . To confirm safety KPT-330 RP2D combination gemcitabine nab-paclitaxel phase II arm study . III . To determine progression free survival ( PFS ) phase II cohort treat gemcitabine , nab-paclitaxel KPT-330 . IV . To determine influence KP-330 , gemcitabine nab-paclitaxel nuclear expression localization tumor suppressor gene protein . OUTLINE : This phase Ib , dose-escalation study selinexor follow phase II . PHASE IB : Patients receive gemcitabine hydrochloride intravenously ( IV ) paclitaxel albumin-stabilized nanoparticle formulation IV weekly ( Mondays ) 3 week . Patients also receive selinexor orally ( PO ) twice weekly ( Mondays Wednesdays ) 4 week . Courses repeat every 4 week absence disease progression unacceptable toxicity . PHASE II : The first 14 patient liver metastasis randomize 1 2 treatment group . Remaining patient assign Group II . GROUP I : Patients receive gemcitabine hydrochloride IV paclitaxel albumin-stabilized nanoparticle formulation IV Phase Ib . Beginning day 3 course 1 , patient also receive selinexor PO twice weekly ( Mondays Wednesdays ) 4 week . Courses repeat every 4 week absence disease progression unacceptable toxicity . GROUP II : Patients receive gemcitabine hydrochloride , paclitaxel albumin-stabilized nanoparticle formulation , selinexor Phase Ib . After completion study treatment , patient follow 2 year .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Acinar Cell</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Written inform consent accordance federal , local , institutional guideline Patients metastatic pancreatic adenocarcinoma treat chemotherapy metastatic disease Eastern Cooperative Oncology Group ( ECOG ) performance status 01 Absolute neutrophil count ( ANC ) &gt; = 1500/mm^3 Platelet count &gt; = 100,000/mm^3 Bilirubin &lt; 2 time upper limit normal ( ULN ) ( except patient Gilbert 's syndrome must total bilirubin &lt; 3 time ULN ) Alanine aminotransferase ( ALT ) &lt; 2.5 time ULN Serum creatinine = &lt; 1.5 mg/dL Serum albumin &gt; = 3.0 g/dL Female patient childbearing potential must agree use dual method contraception negative serum pregnancy test screening , male patient must use effective barrier method contraception sexually active female childbearing potential ; acceptable method contraception condom contraceptive foam , oral , implantable injectable contraceptive , contraceptive patch , intrauterine device , diaphragm spermicidal gel , sexual partner surgically sterilize postmenopausal ; male female patient , effective method contraception must use throughout study three month follow last dose Patients history previously treat malignancy evidence disease last five year allow participate Patients pregnant lactate Radiation , chemotherapy , immunotherapy anticancer therapy = &lt; 3 week prior cycle 1 day 1 ; mitomycin C radioimmunotherapy 6 week prior cycle 1 day 1 Major surgery within four week cycle 1 day 1 Unstable cardiovascular function : Symptomatic ischemia , Uncontrolled clinically significant conduction abnormality ( e.g . : ventricular tachycardia antiarrhythmic exclude 1st degree atrioventricular [ AV ] block asymptomatic leave anterior fascicular block [ LAFB ] /right bundle branch block [ RBBB ] exclude ) , Congestive heart failure ( CHF ) New York Heart Association ( NYHA ) class &gt; = 3 , Myocardial infarction ( MI ) within 3 month cycle 1 day 1 dose Uncontrolled active infection require parenteral antibiotic , antiviral , antifungal within one week prior first dose Known HIV seropositive antiHIV drug unknown interaction drug study agent Known active hepatitis A , B , C infection ; know positive hepatitis C virus ( HCV ) ribonucleic acid ( RNA ) HBsAg ( hepatitis B virus [ HBV ] surface antigen ) Patients active central nervous system ( CNS ) malignancy ; asymptomatic small lesion consider active ; treat lesion may consider inactive stable least 3 month Patients significantly diseased obstruct gastrointestinal tract uncontrolled vomit diarrhea Grade &gt; = 2 peripheral neuropathy within 14 day prior cycle 1 day 1 History seizure , movement disorder cerebrovascular accident within past 5 year prior cycle 1 day 1 Patients muscular degeneration , uncontrolled glaucoma , markedly decrease visual acuity base physician 's assessment Serious psychiatric medical condition could interfere treatment Participation investigational anticancer study within 3 week prior cycle 1 day 1 Concurrent therapy approve investigational anticancer therapeutic Presence clinically significant ascites</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>